Table 5.
Clinical details of ICT rechallenged patients who received targeted immunosuppression for initial irAE
| Pt. | Age | Sex | OS from ICT1 (Mo.) | PFS from ICT1 (Mo.) | Primary cancer | ICT1 | Initial irAE | Initial irAE grade | Initial irAE steroid | Other immune suppression for initial irAE | ICT rechallenge drug | Imaging response after rechallenge | Same irAE after rechallenge | Subs. irAE | Subs. irAE grade | Other immune suppression for subs. irAE |
| 16 | 53 | M | 19.6 | 4.8 | RCC | Anti-CTLA-4+Anti-PD-(L)1 | Hepatitis | 4 | Yes | Mycophenolate mofetil | Anti-PD-(L)1+TKI | PR | No | Hypothyroid | 2 | None |
| 47 | 50 | M | 30.7 | 10.4 | RCC | Anti-CTLA-4+Anti-PD-(L)1+TKI | Colitis/diarrhea | 3 | Yes | Vedolizumab+FMT | Anti-PD-(L)1 monotherapy | PD | No | None | None | None |
| 9 | 49 | M | 10.9 | 3 | RCC | Anti-CTLA-4 monotherapy | Colitis/diarrhea | 3 | Yes | Infliximab | Anti-PD-(L)1+TKI | PD | No | None | None | None |
| 43 | 50 | M | 28.9 | 12.5 | RCC | Anti-PD(L)1+other | Colitis/diarrhea | 2 | Yes | Vedolizumab | Anti-PD-(L)1+TKI | PR | No | Hepatitis | 2 | None |
| 57 | 56 | M | 34.6 | 33.4 | RCC | Anti-PD-(L)1+TKI | Colitis/ diarrhea | 2 | Yes | Mesalamine | Anti-PD-(L)1+TKI | CR | Yes | Colitis/diarrhea | 1 | None |
| 13 | 65 | M | 6 | 3.7 | RCC | Anti-PD-(L)1 monotherapy | Colitis/ diarrhea | 3 | Yes | Vedolizumab | Anti-PD-(L)1 monotherapy | PR | No | None | None | None |
| 38 | 59 | M | 16.8 | 10.3 | RCC | Anti-PD-(L)1+TKI | Colitis/ diarrhea | 1* | Yes | Infliximab | Anti-PD-(L)1+TKI | SD | No | None | None | None |
| 49 | 68 | F | 27.3 | 10.5 | UC | Anti-CTLA-4+Anti-PD-(L)1 | Psoriasis | 2 | No | Secukinumab | Anti-PD-(L)1 | CR | No | None | None | None |
| 42 | 64 | M | 26.6 | 12.5 | UC | Anti-PD(L)1+other | Arthritis | 2 | Yes | Tocilizumab | Anti-PD-(L)1+other | PR | Yes | Arthralgia | 1 | Tocilizumab |
| 34 | 70 | F | 25.3 | 22.2 | UC | Anti-PD(L)1+other | Arthritis | 2 | Yes | Tocilizumab | Anti-PD-(L)1+other | SD | Yes | Arthritis | 2 | Tocilizumab |
| 3 | 47 | M | 20.2 | 2.1 | Prostate cancer | Anti-CTLA-4+Anti-PD-(L)1 | Colitis/ diarrhea | 2 | No | Mesalamine | Anti-PD-(L)1 monotherapy | PD | No | None | None | None |
| 22 | 76 | M | 16.5 | 7.1 | Prostate cancer | Anti-CTLA-4 monotherapy | Colitis/ diarrhea | 1 | No | Mesalamine | Anti-CTLA-4 monotherapy | SD | Yes | Colitis/diarrhea | 3 | Vedolizumab |
| 2 | 55 | M | 13.1 | 1.8 | Prostate cancer | Anti-CTLA-4+Anti-PD-(L)1 | Colitis/diarrhea | 1 | No | Mesalamine | Anti-CTLA-4+anti-PD-(L)1 | PD | Yes | Pneumonitis colitis/ diarrhea |
2 2 |
None |
*Patient treated with infliximab for persistent symptoms despite steroids.
CR, complete response; CTLA-4, cytotoxic T lymphocyte-associated protein-4; FMT, fecal microbiota transplantation; ICT, immune checkpoint therapy; irAE, immune-related adverse event; Mo., month; OS, overall survival; PD, progressive disease; PD-L1, programmed death-ligand 1; PFS, progression free survival (radiographic PFS for prostate cancer); PR, partial response; Pt., patient; RCC, renal cell carcinoma; SD, stable disease; Subs., subsequent; TKI, tyrosine kinase inhibitor; UC, urothelial carcinoma.